DSIP
An endogenous 9-amino-acid peptide named for its ability to induce delta-wave sleep in early rabbit experiments, with broader effects on stress response, pain modulation, and circadian regulation.
Delta sleep-inducing peptide, isolated in 1977 by Monnier and Schoenenberger from rabbit cerebral venous blood during artificial induction of delta sleep, with documented effects on sleep architecture, stress tolerance, and chronic pain in limited human studies.
Mechanism of action
Mechanism incompletely characterized. Proposed mechanisms include modulation of hypothalamic GABA and serotonin signaling, regulation of ACTH and cortisol secretion, and direct effects on delta-wave generation in thalamocortical circuits. Does not appear to act through a single specific receptor; multiple low-affinity binding sites have been described.
Primary uses
- Sleep research
- Chronic pain research (limited human data)
- Alcohol and opioid withdrawal research
- Community use for insomnia
Typical dosing
Community dosing only; no clinical standard.
Regulatory status
Not approved. Research peptide with limited human trials, mostly from Eastern European groups in the 1980s–1990s. Never commercially developed.
References
- [pubmed] Schoenenberger GA. "Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP)." Eur Neurol, 1984;23:321-345.
- [pubmed] Sudakov KV, et al. "Delta sleep-inducing peptide and nootropic drugs eliminate electroencephalographic and autonomic signs of emotional stress." Neurosci Behav Physiol, 1995;25:403-410.
Related peptides
This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.